Jade Biosciences, Inc.

JBIO · Nasdaq · United States

Share price · JBIO

$15.49-8.06 (-34.23%) 3M

close as of 2026-11-18 · 24h delayed · vol 792K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when JBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+5.1%
  2. 23 Sep 2026-12.2%
  3. 4 Aug 2026+11.5%

    Nothing announced by JBIO that day or the session before.

  4. 23 Jun 2026+13.0%

    Nothing announced by JBIO that day or the session before.

  5. 22 Jun 2026+15.6%

    Nothing announced by JBIO that day or the session before.

  6. 8 Jun 2026-11.6%

    Nothing announced by JBIO that day or the session before.

  7. 1 Jun 2026-11.6%
  8. 29 Apr 2026-15.6%

    Nothing announced by JBIO that day or the session before.

  9. 22 Apr 2026+10.3%
  10. 16 Apr 2026+13.6%

    Nothing announced by JBIO that day or the session before.

Share of unusual movement by asset

For each asset, the share of JBIO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
JADE101
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—59%
Sessions with no dated event—41%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
APRIL (A Proliferation-Inducing Ligand, TNFSF13)Monoclonal antibody
IgA Nephropathy
Phase 1
BAFF receptor (BAFFR/BR3)Monoclonal antibody
Rheumatoid Arthritis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (2)
January 2029 (1)
JADE101Phase 2IgA Nephropathy
Est. primary completion 2029-01 · NCT07541287 · CT.gov ↗
What to watch
June 2029 (1)
JADE101Phase 3IgA Nephropathy (IgAN)
Est. primary completion 2029-06 · NCT07902817 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$31M$80M+ $395M short-term inv.$35M-$29M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$50M$107M+ $354M short-term inv.$56M-$44M operating cash flowreport ↗
2026-Q1—$36M$55M+ $256M short-term inv.$40M-$24M operating cash flowreport ↗
2025-Q3—$22M$50M+ $149M short-term inv.$25M-$22M operating cash flowreport ↗
2025-Q2—$23M$221M$32M-$37M operating cash flowreport ↗
2025-Q1—$20M$44M+ $32M short-term inv.$2.5M-$2.4M operating cash flowreport ↗
2024-Q3—$10M$31M+ $58M short-term inv.$16M-$16M operating cash flowreport ↗
2024-Q2—$21M$31M+ $73M short-term inv.$25M-$20M operating cash flowreport ↗
2024-Q1—$20M$9.1M+ $90M short-term inv.$23M-$24M operating cash flowreport ↗
2023-Q3—$17M$32M+ $103M short-term inv.$20M-$16M operating cash flowreport ↗
2023-Q2—$16M$61M+ $89M short-term inv.$19M-$15M operating cash flowreport ↗
2023-Q1—$13M$27M+ $92M short-term inv.$17M-$11M operating cash flowreport ↗
2022-Q3—$11M$22M+ $120M short-term inv.$14M-$9.7M operating cash flowreport ↗
2022-Q2—$8.4M$27M+ $125M short-term inv.$12M-$8.9M operating cash flowreport ↗
2022-Q1—$7.3M$28M+ $133M short-term inv.$11M-$5.7M operating cash flowreport ↗
2021-Q3—$3.4M$181M$6.2M-$6.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$93M$88M+ $248M short-term inv.$32M-$95M operating cash flowreport ↗

Jade Biosciences reported no revenue for fiscal year 2025. R&D spend was $93.12M, up 75.1% YoY; cash and equivalents were $88.44M, while total cash, cash equivalents, and investments were $336.2M as of December 31, 2025. The company reported a net loss of $127.41M for the full year.

Management guided that existing cash is expected to fund operations and capital expenditures into the first half of 2028. JADE101 Phase 1 healthy-volunteer interim data are expected in Q2 2026, with a Phase 2 trial in IgA nephropathy expected to begin mid-2026 and preliminary data anticipated in 2027. JADE201 is expected to enter a first-in-human trial in rheumatoid arthritis in Q2 2026, with interim data anticipated in 2027; JADE301 is expected to enter a Phase 1 trial in the first half of 2027. Jade also completed two private placement financings in Q4, generating gross proceeds of approximately $180M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$53M$34M+ $45M short-term inv.$17M-$71M operating cash flowreport ↗
2023-FY—$64M$23M+ $99M short-term inv.$19M-$57M operating cash flowreport ↗
2022-FY—$39M$22M+ $107M short-term inv.$13M-$39M operating cash flowreport ↗
2021-FY—$15M$54M+ $113M short-term inv.$5.7M-$27M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-25Eisner Mark · directorAward / grant (derivative)47,675——Form 4
2026-06-09Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest IV L.P.; Kiselak Tomas; Harwin Peter Evan · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerAward / grant (derivative)34,843——Form 4
2026-06-09Lavelle Erin · directorAward / grant (derivative)34,843——Form 4
2026-06-09Klein Lawrence Otto · directorAward / grant (derivative)34,843——Form 4
2026-06-09DOBMEIER ERIC · directorAward / grant (derivative)34,843——Form 4
2026-06-09CAIN CHRISTOPHER W. · directorAward / grant (derivative)34,843——Form 4
2026-02-12King Andrew James · See RemarksAward / grant41,250——Form 4
2026-02-12Frohlich Tom · director, Chief Executive OfficerAward / grant78,750——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 120 reporting institutions held 51.4M shares ($735.7M, 74.3% of shares outstanding).

#InstitutionSharesValue
1FMR LLC7,085,423$99.6M
2Fairmount Funds Management LLC4,553,494$64.0M
3Avidity Partners Management LP2,801,416$53.9M
4RA CAPITAL MANAGEMENT, L.P.3,671,083$51.6M
5Bellevue Group AG3,501,502$49.2M
6Venrock Adviser, LLC3,220,364$45.2M
7JANUS HENDERSON GROUP PLC3,105,669$43.6M
8BlackRock, Inc.2,313,949$32.5M
9VANGUARD CAPITAL MANAGEMENT LLC1,796,652$25.2M
10BAKER BROS. ADVISORS LP1,641,137$23.1M
11Remedium Capital Partners, LLC1,577,750$22.2M
12Versant Venture Management, LLC1,525,820$21.4M
13SAMSARA BIOCAPITAL, LLC968,798$13.6M
14GREAT POINT PARTNERS LLC964,462$13.6M
15MARSHALL WACE, LLP944,776$13.3M